Remember Netscape? That scrappy browser company that went public in 1995 with zero revenue and somehow convinced the world it was worth billions? Its stock doubled on day one, and suddenly everyone wanted a piece of the internet revolution. Well, buckle up. Anthropic just made Netscape look like a lemonade stand. Here's the wild part: Anthropic went from a $1 billion annual revenue run rate in January 2025 to $30 billion in just 15 months. But that's not even the crazy part. From February to April 2026 alone? The company more than doubled again. We're talking about 10,000% annualized growth....

So the market's been acting like a toddler on a sugar rush—one minute it's up, the next it's spiraling because of geopolitical drama. If you've got $10,000 burning a hole in your pocket and you're wondering where to throw it without losing sleep, we asked nine Wall Street heavyweights exactly that. Their answers? Surprisingly diverse, which is either reassuring or terrifying depending on your risk tolerance. The Consensus Play: Mega-Cap Tech (But Cheaper Now) Several pros are eyeing the "Magnificent Seven"—Nvidia, Amazon, Apple, Microsoft, Tesla, Meta, and Alphabet—because they've actually g...

Once upon a time, Beyond Meat was worth $14 billion. Today it’s a penny stock fighting to stay listed on Nasdaq. The story of BYND’s fall from grace is one of the cleanest cautionary tales the market has produced in years — and it’s not over yet. The company filed its long-overdue 2025 annual report this week, which satisfied one Nasdaq listing requirement. But it still faces a second hurdle: its share price needs to trade above $1 for an extended period to avoid delisting. That’s not a minor bureaucratic nuisance. Losing a Nasdaq listing would cut off Beyond Meat’s primary mechanism for rais...

Novo Nordisk just handed the obesity drug market a new gear. The Danish pharma giant launched Wegovy HD — a higher-dose 7.2 mg version of its blockbuster weight-loss drug — across more than 70,000 U.S. pharmacies this week. For patients who stalled on the standard 2.4 mg dose, this is a meaningful clinical upgrade. The numbers are striking. In the 72-week STEP UP trial, patients on Wegovy HD lost about 21% of body weight on average when they stayed on treatment. That compares to roughly 16% on the existing 2.4 mg dose. Even more compelling: 31.2% of Wegovy HD patients shed at least 25% of the...

Here’s a counterintuitive thesis from a veteran market strategist: the best way to profit from the AI boom might be to stop chasing AI stocks altogether. Eric Fry, the macro investor who correctly called the dot-com bust and loaded up on "boring" non-tech plays while Cisco and Microsoft cratered 50%+, says history is rhyming again. Back in 2000-2002, he recommended shorting Softbank, Cisco, and Motorola while buying Thai hotel companies, copper miners, and French luxury brands. The result? Triple-digit gains while the Nasdaq imploded. His name for the current opportunity: "AI Survivors" — com...

Earnings season is basically the Super Bowl of the stock market—everyone's watching, everyone's nervous, and someone's definitely going to surprise you. Citi just dropped a playbook for investors looking to capitalize on the chaos, and it's worth paying attention to. The bank identified 16 stocks it thinks are sitting on a goldmine of upside that Wall Street hasn't fully priced in yet. We're talking 3% to 12% pops when these companies report their Q1 numbers. That's the kind of move that makes portfolios smile. Here's the thing: consensus estimates got bumped up in March, which is great. But...

When the market sells off, the usual suspects come out with their predictions. Strategists warn of further downside. Retail investors panic-sell. But there is one group that tends to cut through the noise with real conviction: corporate insiders. These are the officers and directors who actually run the companies, see the order books, and know whether the business is genuinely deteriorating or just temporarily battered by headlines.Here is the surprising part: despite March's significant stock market decline, corporate insiders as a group became slightly more bullish, not less. According to da...

This is shaping up to be one of the most interesting bank earnings seasons in years. Yes, the macro backdrop is messy: an Iran war, oil volatility, a Fed that cannot make up its mind, and a consumer that is starting to crack. But here is the thing: the largest U.S. banks are heading into results week trading at lower forward P/E ratios than they were at the end of 2025, even as earnings estimates have actually been revised higher for most of them. That is a setup worth paying attention to.The parade starts Monday when Goldman Sachs (GS) reports Q2, followed by JPMorgan Chase (JPM), Citigroup (...

It's official: the Strait of Hormuz — the narrow chokepoint through which roughly 20% of the world's oil flows — is now under U.S. blockade. President Trump announced Sunday morning that the U.S. Navy will begin blocking all ships trying to enter or exit the strait, after peace talks with Iran collapsed in Islamabad. Markets that were banking on a de-escalation just got a cold bucket of water thrown on them.Here's the immediate math: the strait handles about 20 million barrels of oil per day. With Iran already restricting access since the war broke out and the U.S. now piling on with a naval b...

The bull market's been on a three-year tear, and Wall Street's asking the obvious question: can it keep going? Here's the thing—most analysts think yes, but they're not all betting the same amount. By late December 2025, the S&P 500 had climbed about 18% for the year, hitting all-time highs around 6,932. That's on top of 24% gains in 2023 and 23% in 2024. The Nasdaq? Up 22.3% to roughly 23,613. Even the Dow got in on the action with a 14.5% gain. Not bad for a market that looked like it might implode in the first four months of the year. The real question isn't whether stocks will go up—it's...